🌟 An update on our exciting progress in learning and predicting the effects of small molecules on the transcriptome! 🌟 transcriptabio.com/post/mast…

Characterizing collections of molecules is an important chemoinformatics task. Beyond annotating molecules by common descriptors, can we gain insight by leveraging LLMs for initial triage? Our prototype app, MolSifter, does just that!

Our Director of Software Engineering, Clayton Mellina, believes a patient-centered approach, coupled with breakthrough technologies in machine learning and high-throughput biology, will drive a revolution in human health. Read more of our conversation: rarebase.org/post/unleashing…

Rarebase has generated a premier drug screening dataset that maximizes efficiency in drug hunting for rare neurological diseases. Learn more about our breakthrough approach to meet the urgent needs of the #raredisease patient community: rarebase.org/post/how-the-ra…

In our latest podcast, Director of High Throughput Biology, Joe Bellucci, PhD, walks us through advances in high-throughput screening and next-generation sequencing that have enabled tailored and scalable approaches to rare disease research. Listen here: spotifyanchor-web.app.link/e…

Neurodevelopmental disorders make up 77% of our current drug discovery portfolio. This National Developmental Disabilities Awareness Month, let's champion support & inclusion for affected individuals with the rare disease community. #DDAM2023

Join us in recognizing #CACNA1A Awareness Day on March 19th! At Rarebase, we partner with the patient organization Miren's Marathon at the Rare Village Foundation in support of those affected by CACNA1A-related conditions. Together, we build a path forward for rare diseases.

Our discovery research team has been gearing up for compound testing in our Preclinical Stage! Our wild-type stem cells are thawed and ready for expansion and differentiation into neurons for concentration-response studies with Function-identified drug repurposing candidates.

We sat down with our Scientific Founder and Advisor, Elizabeth Iorns, PhD, to dive into the science and technology behind the Rarebase drug discovery strategy. Read more here: rarebase.org/post/reimaginin…

We are committed to making a difference in the lives of those affected by rare diseases and we look forward to supporting #RareDiseaseDay next week. Sign up for our newsletter to follow our journey: eepurl.com/hKNGWr

Tomorrow is International Day of Women and Girls in Science 🧬🔬🚀 We are grateful to all the women on the Rarebase team for your tireless work to foster partnerships with patient organizations and drive our precision medicine research forward for the #raredisease community.

Our #precisionmedicine platform Function identifies #drugrepurposing candidates that have the potential to target the root cause biology of rare genetic diseases. Discover how we identify these candidates based on common types of genetic variants: rarebase.org/post/how-does-r…

Next week our CSO, Chris Moxham, PhD, will give a showcase talk titled “Accelerating a Path Forward for #RareDisease #DrugDiscovery” @PMWCintl on January 27, 2023 in Santa Clara, CA. We are excited to share our insights on scalable approaches for precision medicine #PMWC23

It's a wrap for 2022 - an incredible year for us at Rarebase! We built the tools and computational platform needed to advance drug discovery for thousands of rare genetic disorders. Here's to another year of innovative collaboration with our partners in 2023! #rarediseases